Preparation and in vitro-in vivo evaluation of Witepsol® H35 based self-nanoemulsifying drug delivery systems (SNEDDS) of coenzyme Q10

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 4, 2010, Pages 224-232

  Nepal, Pushp R ^a   Han, Hyo Kyung ^a   Choi, Hoo Kyun ^a  

^a Chosun University   (South Korea)

Author keywords

Bioavailability; Coenzyme Q10; Lauroglycol FCC; Self nanoemulsifying drug delivery systems (SNEDDS); Solutol HS15; Witepsol H35

Indexed keywords

CREMOPHOR; DIETHYLENE GLYCOL MONOETHYL ETHER; EMULSIFYING AGENT; LABRAFAC; LABRAFAC CM 10; LAUROGLYCOL; LAUROGLYCOL FCC; POLYSORBATE 80; SOLUTOL HS 15; SOTULOL; TWEEN; UBIDECARENONE; UNCLASSIFIED DRUG; WITEPSOL; WITEPSOL H 35;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NONHUMAN; PH; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; EMULSIFYING AGENTS; MALE; NANOTECHNOLOGY; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES; UBIQUINONE;

EID: 75149137336     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.12.004     Document Type: Article

References (22)

1. Abismail B., Canselier J.P., Wilhelm A.M., Delmas H., and Gourdon C. Emulsification by ultrasound: drop size distribution and stability. Ultrason. Sonochem. 6 (1999) 75-83
2. 10 by self-emulsifying drug delivery systems. Int. J. Pharm. 374 (2009) 66-72
3. Craig D.Q.M., Barker S.A., Banning D., and Booth S.W. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int. J. Pharm. 114 (1995) 103-110
4. Driscoll D.F., Nehne J., Peterss H., Franke R., Bistrian B.R., and Niemann W. The influence of medium-chain triglycerides on the stability of all-in-one formulations. Int. J. Pharm. 240 (2002) 1-10
5. Fernandez P., Andre V., Rieger J., and Kuhnle A. Nano-emulsion formation by emulsion phase inversion. Colloid Surf. A 251 (2004) 53-58
6. 10: a new drug for cardiovascular disease. J. Clin. Pharmacol. 30 (1990) 590-608
7. 10 in plasma. J. Chromatogr. 593 (1992) 217-226
8. Gursoy R.N., and Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58 (2004) 173-182
9. Hong J.Y., Kim J.K., Song Y.K., Park J.S., and Kim C.K. A new self emulsifying formulation of itraconazole with improved dissolution and oral absorption. J. Control. Rel. 110 (2006) 332-338
10. Jiang H., Moon K.S., Dong H., Hua F., and Wong C.P. Size-dependent melting properties of tin nanoparticles. Chem. Phys. Lett. 429 (2006) 492-496
11. Kommuru T.R., Gurley B., Khan M.A., and Reddy I.K. Self-emulsifying drug delivery systems (SEDDS) of Coenzyme Q10: formulation development and bioavailability assessment. Int. J. Pharm. 212 (2001) 233-246
12. Narang A.S., Delmarre D., and Gao D. Stable drug encapsulation in micelles and microemulsions. Int. J. Pharm. 345 (2007) 9-25
13. Nazzal S., Smalyukh I.I., Lavrentovich O.D., and Khan M.A. Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation. Int. J. Pharm. 235 (2002) 247-265
14. Pouton C.W. Formulation of self-emulsifying drug delivery systems. Adv. Drug Deliv. Rev. 25 (1997) 47-58
15. 10 as a migraine preventive. Cephalalgia 22 (2002) 137-141
16. 10 in rats. Asian Pacific J. Cancer Prev. 7 (2006) 599-603
17. Shafiq S., Shakeel F., Talegaonkar S., Ahmad F.J., Khar R.K., and Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur. J. Pharm. Biopharm. 66 (2007) 227-243
18. Snchez M.C., Berjano M., Guerrero A., and Gallegos C. Emulsification rheokinetics of nonionic surfactant-stabilized oil-in-water emulsions. Langmuir 17 (2001) 5410-5416
19. Stott P.W., Williams A.C., and Barry B.W. Mechanistic study into the enhanced transdermal permeation of a model β-blocker, propranolol, by fatty acids: a melting point depression effect. Int. J. Pharm. 219 (2001) 161-176
20. Suzuki H., Onishi H., Takahashi Y., Iwata M., and Machida Y. Development of oral acetaminophen chewable tablets with inhibited bitter taste. Int. J. Pharm. 251 (2003) 123-132
21. Volsov, A., 2000. Pharmaceutical compositions containing low melting wax. WIPO, International patent application number: PCT/IL99/00365, International publication dates: 13.01.2000.
22. Wang L., Dong J., Chen J., Eastoe J., and Li X. Design and optimization of new self-nanoemulsifying drug delivery system. J. Colloid Interf. Sci. 330 (2009) 443-448